Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats

Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H866-73. doi: 10.1152/ajpheart.01232.2008. Epub 2009 Jun 26.

Abstract

Systemic inflammation induces a multiple organ dysfunction syndrome that contributes to morbidity and mortality in septic patients. Since increasing plasma apolipoprotein A-I (apoA-I) and HDL may reduce the complications of sepsis, we tested the hypothesis that the apoA-I mimetic peptide 4F confers similar protective effects in rats undergoing cecal ligation and puncture (CLP) injury. Male Sprague-Dawley rats were randomized to undergo CLP or sham surgery. IL-6 levels were significantly elevated in plasma by 6 h after CLP surgery compared with shams. In subsequent studies, CLP rats were further subdivided to receive vehicle or 4F (10 mg/kg) by intraperitoneal injection, 6 h after sepsis induction. Sham-operated rats received saline. Echocardiographic studies showed a reduction in left ventricular end-diastolic volume, stroke volume, and cardiac output (CO) 24 h after CLP surgery. These changes were associated with reduced blood volume and left ventricular filling pressure. 4F treatment improved blood volume status, increased CO, and reduced plasma IL-6 in CLP rats. Total cholesterol (TC) and HDL were 79 +/- 5 and 61 +/- 4 mg/dl, respectively, in sham rats. TC was significantly reduced in CLP rats (54 +/- 3 mg/dl) due to a reduction in HDL (26 +/- 3 mg/dl). 4F administration to CLP rats attenuated the reduction in TC (69 +/- 4 mg/dl) and HDL (41 +/- 3 mg/dl) and prevented sepsis-induced changes in HDL protein composition. Increased plasma HDL in 4F-treated CLP rats was associated with an improvement in CO and reduced mortality. It is proposed that protective effects of 4F are related to its ability to prevent the sepsis-induced reduction in plasma HDL.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoprotein A-I / immunology*
  • Blood Pressure / drug effects
  • Blood Pressure / immunology
  • Blood Volume / drug effects
  • Blood Volume / immunology
  • Echocardiography
  • Inflammation* / drug therapy
  • Inflammation* / immunology
  • Inflammation* / mortality
  • Interleukin-6 / blood
  • Lipoproteins, HDL / blood
  • Male
  • Molecular Mimicry / immunology
  • Peptides / immunology
  • Peptides / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Sepsis* / drug therapy
  • Sepsis* / immunology
  • Sepsis* / mortality
  • Stroke Volume / drug effects
  • Stroke Volume / immunology
  • Ventricular Function, Left / drug effects*
  • Ventricular Function, Left / immunology*

Substances

  • Apolipoprotein A-I
  • Interleukin-6
  • Lipoproteins, HDL
  • Peptides